Hgh eod study dosage

The effects of biosynthetic methionyl-human growth hormone (met-hGH) on body composition and endogenous secretion of growth hormone (GH) and insulin-like growth factor I (IGF-I) were studied in eight well-trained exercising adults between 22 and 33 yr of age for 6 weeks.

Dosing & Administration:

The met-hGH (experimental) treatment consisted of 8.0 mg (2 U/mg) per week of methGH (Protropin; Genentech, San Francisco, CA), which was divided into three doses (2.67 mg/dose) and delivered on alternate days (3 days/wk) in 0.5 ml of bacteriostatic diluent. Because of differences in the body weights of the subjects, the relative dose range varied between 0.03 and 0.05 mg/kg per injection. Injections were given between 0800 and 1500, and their delivery was rotated among four to six sites throughout the study period. Treatments were administered on a double-blind basis with neither the experimental subject nor the person administering the injections knowing which treatment was being delivered. The total weekly dose of met-hGH used in this study (8.0 mg) was considered supraphysiological, since the spontaneous release of human GH during a 24-h period is purportedly -0.68 mg (4.8 mg/wk) in men and 0.79 mg (5.5 mg/wk) in women (30), similar to amounts reported by others (6).

CONCLUSION

In the present study, we found that alternate-day treatment with met-hGH altered body composition in highly conditioned, exercising adults by increasing FFW (fat free weight), decreasing %fat, and increasing FFW (fat free weight)/FW (fat weight). These changes were significantly greater than those produced by exercise alone.

...

Moreover we found that supraphysiological amounts of met-hGH were sufficient to significantly elevate circulating concentrations of IGF-I in all our subjects, confirming that the changes in body composition were indeed due to real alterations produced in vivo by the hormone treatment.